Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 (At-211) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

Automated summary

Astatine-211 is a top candidate for targeted alpha therapy (TAT) due to its physical properties. In this article, we summarize the results of completed clinical trials, provide an overview of ongoing trials, and discuss future prospects.